NCT06035744View on ClinicalTrials.gov

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

CLN-617

Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences

DRUG

Pembrolizumab

Humanized IgG4 anti-PD-1 monoclonal antibody

Trial Locations (5)

32806

RECRUITING

Orlando Health, Orlando

60637

NOT_YET_RECRUITING

University of Chicago, Chicago

77030

RECRUITING

MD Anderson, Houston

90033

NOT_YET_RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

Sponsors
All Listed Sponsors
lead

Cullinan Therapeutics Inc.

INDUSTRY

NCT06035744 - CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter